Gastroesophageal Adenocarcinoma (gastric, gastroesophageal junction, and esophageal adenocarcinoma)
Adenocarcinoma arising in the stomach, the gastroesophageal junction, or the distal esophagus. Grouped as a single indication because these sites share tumor biology, staging, and treatment approach.
Biomarkers used in this indication
Each approval combines this indication with specific biomarker criteria and a therapy. Select a therapy from the tables below to open its FDA-defined testing pathway.
Defined explicitly for Gastroesophageal Adenocarcinoma (gastric, gastroesophageal junction, and esophageal adenocarcinoma) in FDA labeling.
Defined at the solid tumor level and applicable to Gastroesophageal Adenocarcinoma (gastric, gastroesophageal junction, and esophageal adenocarcinoma) and other solid tumor cancers.
Therapies with biomarker-defined approvals
Each therapy below has at least one FDA companion diagnostic approval tied to Gastroesophageal Adenocarcinoma (gastric, gastroesophageal junction, and esophageal adenocarcinoma). Select a therapy to view the specific approval and eligible tests.
deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High)
deficient mismatch repair (dMMR) proteins (MLH1, PMS2, MSH2 and MSH6); MSI-High (Microsatellite instability-High); TMB (TMB ≥ 10 mutations per megabase)
RET (fusions)
NTRK1, NTRK2 and NTRK3 (fusions)
NTRK1, NTRK2 and NTRK3 (fusions)
ERBB2 (HER2) (Gene amplification (ISH amplified)); ERBB2 (HER2) (HER-2 protein overexpression (IHC3+))